AAVantgarde secures $141m Series B funding to advance its gene therapies for inherited retinal diseases.
Amount Raised
$141 Million
Round Type
Series B
MilanBiotechnologyHealth CareGeneticsTherapeuticsresearchDescription
AAVantgarde has secured $141 million in Series B funding focused on advancing its clinical programs for inherited retinal diseases. This financing will support the development of AAVB-039 for Stargardt disease and AAVB-081 for Usher 1B. The therapies aim to treat the root causes of these conditions. CEO Dr Natalia Misciattelli emphasized the validation of their team and science through this investment.
Quick answer
AAVantgarde Bio raised $141 Million in a Series B round, dated November 3, 2025. AAVantgarde Bio is based in Milan, Lombardy, Italy.
- How much did AAVantgarde Bio raise?
- AAVantgarde Bio raised $141 Million in a Series B round on November 3, 2025.
- What does AAVantgarde Bio do?
- AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity..
- Where is AAVantgarde Bio based and how big is it?
- AAVantgarde Bio is based in Milan, Lombardy, Italy. Fundz records about 48 employees.
- Who are the decision-makers at AAVantgarde Bio?
- Fundz holds 5 contacts at AAVantgarde Bio, including the Vice President Project Management and Information Technology. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Genetics and Therapeutics around the same time
Companies in the same sectors as AAVantgarde Bio that raised within 45 days of this round, from Fundz verified event records.
- Precision BioSciences raised $66M (Funding Round) on November 12, 2025.
- Brainstorm Cell Therapeutics raised $155K (Convertible Note) on November 6, 2025.
- Grail raised $325M (Post-IPO Equity) on October 20, 2025.
- Faeth Therapeutics raised $25M (Funding Round) on October 20, 2025.
- Aarvik Therapeutics raised an undisclosed amount (Seed) on September 29, 2025.
- Corner Therapeutics raised $17M on September 26, 2025.
Who to call at AAVantgarde Bio, and when
A new round usually means AAVantgarde Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day AAVantgarde Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AAVantgarde Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AAVantgarde Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AAVantgarde Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAAVantgarde Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.